The FURI Study: Patient Outcomes After Treatment with Oral Ibrexafungerp Based on Prior Antifungal Therapy and Patient Enrollment Criteria

Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022

Oral Ibrexafungerp Outcomes in Patients with Invasive Candidiasis and Candidemia from the FURI and CARES Studies

Oliver Cornely, M.D. (Cologne, Germany)
ECCMID, April 2022

Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study

R.S. Siebert, M.D. (Pretoria, South Africa)
ECCMID, April 2022

Outcomes of Oral Ibrexafungerp in Refractory Patients from an Interim Analysis of a Phase 3 Open-Label Study (FURI)

TIMM 2021, October 2021

Outcomes of Oral Ibrexafungerp by Pathogen from Two Open-label Studies of Patients with Serious Fungal Infections (FURI and CARES)

TIMM 2021, October 2021

Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal Candidiasis and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI)

IDWeek, September 2021

Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)

IDWeek, September 2021

Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

BD Alexander, OA Cornely, PG Pappas, R Miller, M Johnson, J Vazquez,  L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli,  TF Patterson, M Hoenigl, N Azie, DA Angulo
ID Week
October 2020

Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including Isolates with Elevated MIC’s to Echinocandins

Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi